[{"orgOrder":0,"company":"Vertice Pharma","sponsor":"Mannkind","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Vertice Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vertice Pharma \/ Vertice","highestDevelopmentStatusID":"12","companyTruncated":"Vertice Pharma \/ Vertice"}]

Find Clinical Drug Pipeline Developments & Deals by Vertice Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Vertice will make a specified quarterly payment to MannKind to defray the costs of the additional promotional activity and will pay MannKind royalties on gross profit resulting from all sales of Thyquidity.

                          Brand Name : Thyquidity

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 17, 2020

                          Lead Product(s) : Levothyroxine Sodium

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Recipient : Mannkind

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank